Thomas P. Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas P. Jacobs has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
John P. Bilezikian
Division of Endocrinology (T.P.J., J.P.B.), Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032
2 shared publicationsGlenville Jones
Department of Biomedical and Molecular Sciences (M.K., G.J.), Queen's University, Kingston, Ontario, Canada K7L 3N6
1 shared publicationKarl-Peter Schlingmann
Department of General Pediatrics (K.-P.S.), University Children's Hospital, 48129 Munster, Germany
1 shared publicationMartin Kaufman
Department of Biomedical and Molecular Sciences (M.K., G.J.), Queen's University, Kingston, Ontario, Canada K7L 3N6
1 shared publicationRajiv Kumar
Nephology Research (R.K.), Departments of Medicine, Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55902
1 shared publication- Sue A. Shapses
Department of Nutritional Sciences, Rutgers University, New Brunswick, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (3) , 708-712
A Lifetime of Hypercalcemia and Hypercalciuria, Finally Explained
Context: Hypercalcemia, hypercalciuria, and recurrent nephrolithiasis are all common clinical problems. This case report illustrates a newly described but possibly not uncommon cause of this presenting complex. Objective: We report on a patient studied for over 30 years, with the diagnosis finally made with modern biochemical and genetic tools. Design and Setting: This study consists of a case report and review of literature conducted in a University Referral Center. Patient and Intervention: A single patient with hypercalcemia, hypercalciuria, and recurrent nephrolithiasis was treated with low-calcium diet, low vitamin D intake, prednisone, and ketoconazole. Main Outcome Measure: We measured the patient's clinical and biochemical response to interventions above. Results: Calcium absorption measured by dual isotope absorptiometry was elevated at 37.4%. Serum levels of 24,25-dihydroxyvitamin D were very low, as measured in two laboratories (0.62 ng/mL [normal, 3.49 ± 1.57], and 0.18 mg/mL). Genetic analysis of CYP24A1 revealed homozygous mutation E143del previously described. The patient's serum calcium and renal function improved markedly on treatment with ketoconazole but not with prednisone. Conclusions: Chronic hypercalcemia, hypercalciuria, and/or nephrolithiasis may be caused by mutations in CYP24A1 causing failure to metabolize 1,25-dihydroxyvitamin D.
- 1 March 2014
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 99 (3) , 708-712
Open AccessA Lifetime of Hypercalcemia and Hypercalciuria, Finally Explained
Context: Hypercalcemia, hypercalciuria, and recurrent nephrolithiasis are all common clinical problems. This case report illustrates a newly described but possibly not uncommon cause of this presenting complex. Objective: We report on a patient studied for over 30 years, with the diagnosis finally made with modern biochemical and genetic tools. Design and Setting: This study consists of a case report and review of literature conducted in a University Referral Center. Patient and Intervention: A single patient with hypercalcemia, hypercalciuria, and recurrent nephrolithiasis was treated with low-calcium diet, low vitamin D intake, prednisone, and ketoconazole. Main Outcome Measure: We measured the patient's clinical and biochemical response to interventions above. Results: Calcium absorption measured by dual isotope absorptiometry was elevated at 37.4%. Serum levels of 24,25-dihydroxyvitamin D were very low, as measured in two laboratories (0.62 ng/mL [normal, 3.49 ± 1.57], and 0.18 mg/mL). Genetic analysis of CYP24A1 revealed homozygous mutation E143del previously described. The patient's serum calcium and renal function improved markedly on treatment with ketoconazole but not with prednisone. Conclusions: Chronic hypercalcemia, hypercalciuria, and/or nephrolithiasis may be caused by mutations in CYP24A1 causing failure to metabolize 1,25-dihydroxyvitamin D.
- 1 November 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (11) , 6316-6322
Rare Causes of Hypercalcemia
Context: Although hypercalcemia is usually caused by primary hyperparathyroidism or malignancy, a number of other conditions can be important to consider. This review considers unusual causes of hypercalcemia that are generally not found in reviews on this subject.Evidence Acquisition: Articles describing rarely reported associations between hypercalcemia and unusual causes were identified through a computer search of the terms hypercalcemia/etiology and through the references listed in those articles. We grouped the 58 different reports into categories defined by a presumed etiology: increased levels of 1,25-dihydroxyvitamin D or PTHrP, occult milk-alkali syndrome, and undefined mechanisms. Reports in infants and children are listed separately, as are reports of pseudohypercalcemia, situations that are not truly hypercalcemic because the ionized calcium is normal.Evidence Synthesis: In some situations, as this review points out, a number of unusual causes of hypercalcemia are important to consider. The search for an elusive cause of hypercalcemia is best accomplished by the most likely potential mechanism. An orderly search in this manner is likely to reveal the underlying cause.Conclusions: That so many patients have been described with rare and usually poorly understood causes of hypercalcemia highlights our incomplete understanding of calcium metabolism in humans and suggests additional areas in which directed clinical investigation might improve our knowledge of the normal metabolism of calcium.
- 1 November 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (11) , 6316-6322
Rare Causes of Hypercalcemia
Context: Although hypercalcemia is usually caused by primary hyperparathyroidism or malignancy, a number of other conditions can be important to consider. This review considers unusual causes of hypercalcemia that are generally not found in reviews on this subject.Evidence Acquisition: Articles describing rarely reported associations between hypercalcemia and unusual causes were identified through a computer search of the terms hypercalcemia/etiology and through the references listed in those articles. We grouped the 58 different reports into categories defined by a presumed etiology: increased levels of 1,25-dihydroxyvitamin D or PTHrP, occult milk-alkali syndrome, and undefined mechanisms. Reports in infants and children are listed separately, as are reports of pseudohypercalcemia, situations that are not truly hypercalcemic because the ionized calcium is normal.Evidence Synthesis: In some situations, as this review points out, a number of unusual causes of hypercalcemia are important to consider. The search for an elusive cause of hypercalcemia is best accomplished by the most likely potential mechanism. An orderly search in this manner is likely to reveal the underlying cause.Conclusions: That so many patients have been described with rare and usually poorly understood causes of hypercalcemia highlights our incomplete understanding of calcium metabolism in humans and suggests additional areas in which directed clinical investigation might improve our knowledge of the normal metabolism of calcium.